AveXis Inc. Names Chief Scientific Officer
Dallas, TX, August 01, 2013 --(PR.com)-- AveXis Inc. (avexisinc.com), a synthetic biology platform company focused on research and development of technology for disease treatment, today announced Dr. Allan A. Kaspar will serve as the company’s first Chief Scientific Officer (CSO).
Dr. Kaspar has held research positions at multiple biotech companies—notably, in early-stage drug development. He joins the AveXis team, bringing over 12 years of experience in the pharmaceutical and biotechnology industries, in cross-functional scientific and business leadership roles. His former position with Pfizer involved overseeing research collaboration with academic and industry partners.
AveXis’ leadership sees Dr. Kaspar’s background as a perfect fit for this key position as the company establishes unique alliances to bring innovative treatments to patients with unmet medical needs. Spinal muscular atrophy (SMA), the most common genetic cause of infant mortality in the world, is the company’s first focus. At this time, there is no medical treatment for SMA.
“As we prepare to enter Phase I clinical trials, the addition of Dr. Kaspar as our CSO indicates our gene replacement therapy for SMA has added yet another extremely talented, experienced and dedicated scientist to our rapidly expanding family—and one which will guide this significant collaboration,” said John A. Carbona, Chief Executive Officer.
Dr. Kaspar received his Bachelor of Science degree from the University of Illinois, earned his Ph.D. in immunology from Stanford University, and carried out postdoctoral research at the Burnham Institute in La Jolla. Dr. Kaspar also holds an MBA from San Diego State University.
For more information about AveXis: 1-855-9-AVEXIS or avexisinc.com.
About Spinal Muscular Atrophy
Spinal muscular atrophy (SMA) is an autosomal-recessive genetic disorder characterized by progressive weakness of the lower motor neurons. SMA is caused by a genetic defect in the SMN1 gene which codes SMN, a protein necessary for survival of motor neurons. SMA kills more infants than any other genetic disease in today's world.
About AveXis Inc.
Based in Dallas, Texas, AveXis is a synthetic biology platform company establishing unique industry alliances to create innovative treatments for people with unmet medical needs. Spinal muscular atrophy (SMA) is the company’s first focus.
Corporate Contact:
John A. Carbona, Chief Executive Officer
972-331-1905 or jc@avexisinc.com
Media Contact:
Kristin Laminack, Director, Marketing and Media
972-331-9626 or kristin@avexisinc.com
Dr. Kaspar has held research positions at multiple biotech companies—notably, in early-stage drug development. He joins the AveXis team, bringing over 12 years of experience in the pharmaceutical and biotechnology industries, in cross-functional scientific and business leadership roles. His former position with Pfizer involved overseeing research collaboration with academic and industry partners.
AveXis’ leadership sees Dr. Kaspar’s background as a perfect fit for this key position as the company establishes unique alliances to bring innovative treatments to patients with unmet medical needs. Spinal muscular atrophy (SMA), the most common genetic cause of infant mortality in the world, is the company’s first focus. At this time, there is no medical treatment for SMA.
“As we prepare to enter Phase I clinical trials, the addition of Dr. Kaspar as our CSO indicates our gene replacement therapy for SMA has added yet another extremely talented, experienced and dedicated scientist to our rapidly expanding family—and one which will guide this significant collaboration,” said John A. Carbona, Chief Executive Officer.
Dr. Kaspar received his Bachelor of Science degree from the University of Illinois, earned his Ph.D. in immunology from Stanford University, and carried out postdoctoral research at the Burnham Institute in La Jolla. Dr. Kaspar also holds an MBA from San Diego State University.
For more information about AveXis: 1-855-9-AVEXIS or avexisinc.com.
About Spinal Muscular Atrophy
Spinal muscular atrophy (SMA) is an autosomal-recessive genetic disorder characterized by progressive weakness of the lower motor neurons. SMA is caused by a genetic defect in the SMN1 gene which codes SMN, a protein necessary for survival of motor neurons. SMA kills more infants than any other genetic disease in today's world.
About AveXis Inc.
Based in Dallas, Texas, AveXis is a synthetic biology platform company establishing unique industry alliances to create innovative treatments for people with unmet medical needs. Spinal muscular atrophy (SMA) is the company’s first focus.
Corporate Contact:
John A. Carbona, Chief Executive Officer
972-331-1905 or jc@avexisinc.com
Media Contact:
Kristin Laminack, Director, Marketing and Media
972-331-9626 or kristin@avexisinc.com
Contact
AveXis Inc.
Kristin Laminack
972-331-9626
www.avexisinc.com
Kristin Laminack
972-331-9626
www.avexisinc.com
Contact
Categories